Historical Valuation
Entera Bio Ltd (ENTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7730.22 is considered Overvalued compared with the five-year average of -4.19. The fair price of Entera Bio Ltd (ENTX) is between 0.11 to 1.57 according to relative valuation methord. Compared to the current price of 1.74 USD , Entera Bio Ltd is Overvalued By 11.02%.
Relative Value
Fair Zone
0.11-1.57
Current Price：1.74
11.02%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Entera Bio Ltd (ENTX) has a current Price-to-Book (P/B) ratio of 5.31. Compared to its 3-year average P/B ratio of 5.83 , the current P/B ratio is approximately -9.00% higher. Relative to its 5-year average P/B ratio of 5.39, the current P/B ratio is about -1.57% higher. Entera Bio Ltd (ENTX) has a Forward Free Cash Flow (FCF) yield of approximately -8.73%. Compared to its 3-year average FCF yield of -20.07%, the current FCF yield is approximately -56.50% lower. Relative to its 5-year average FCF yield of -21.03% , the current FCF yield is about -58.49% lower.
P/B
Median3y
5.83
Median5y
5.39
FCF Yield
Median3y
-20.07
Median5y
-21.03
Competitors Valuation Multiple
AI Analysis for ENTX
The average P/S ratio for ENTX competitors is 1429.29, providing a benchmark for relative valuation. Entera Bio Ltd Corp (ENTX.O) exhibits a P/S ratio of 7730.22, which is 440.84% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ENTX
1Y
3Y
5Y
Market capitalization of ENTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ENTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ENTX currently overvalued or undervalued?
Entera Bio Ltd (ENTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7730.22 is considered Overvalued compared with the five-year average of -4.19. The fair price of Entera Bio Ltd (ENTX) is between 0.11 to 1.57 according to relative valuation methord. Compared to the current price of 1.74 USD , Entera Bio Ltd is Overvalued By 11.02% .
What is Entera Bio Ltd (ENTX) fair value?
ENTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Entera Bio Ltd (ENTX) is between 0.11 to 1.57 according to relative valuation methord.
How does ENTX's valuation metrics compare to the industry average?
The average P/S ratio for ENTX's competitors is 1429.29, providing a benchmark for relative valuation. Entera Bio Ltd Corp (ENTX) exhibits a P/S ratio of 7730.22, which is 440.84% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Entera Bio Ltd (ENTX) as of Jan 09 2026?
As of Jan 09 2026, Entera Bio Ltd (ENTX) has a P/B ratio of 5.31. This indicates that the market values ENTX at 5.31 times its book value.
What is the current FCF Yield for Entera Bio Ltd (ENTX) as of Jan 09 2026?
As of Jan 09 2026, Entera Bio Ltd (ENTX) has a FCF Yield of -8.73%. This means that for every dollar of Entera Bio Ltd’s market capitalization, the company generates -8.73 cents in free cash flow.
What is the current Forward P/E ratio for Entera Bio Ltd (ENTX) as of Jan 09 2026?
As of Jan 09 2026, Entera Bio Ltd (ENTX) has a Forward P/E ratio of -3.22. This means the market is willing to pay $-3.22 for every dollar of Entera Bio Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Entera Bio Ltd (ENTX) as of Jan 09 2026?
As of Jan 09 2026, Entera Bio Ltd (ENTX) has a Forward P/S ratio of 7730.22. This means the market is valuing ENTX at $7730.22 for every dollar of expected revenue over the next 12 months.